|
1
|
Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments.
|
Bioinformatics
|
2004
|
4.58
|
|
2
|
Feature extraction and quantification for mass spectrometry in biomedical applications using the mean spectrum.
|
Bioinformatics
|
2005
|
4.26
|
|
3
|
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
|
Clin Cancer Res
|
2012
|
3.48
|
|
4
|
Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer.
|
J Natl Cancer Inst
|
2005
|
3.31
|
|
5
|
Non-parametric quantification of protein lysate arrays.
|
Bioinformatics
|
2007
|
3.18
|
|
6
|
Functional proteomic profiling of AML predicts response and survival.
|
Blood
|
2008
|
2.90
|
|
7
|
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
|
J Natl Cancer Inst
|
2012
|
2.79
|
|
8
|
Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins.
|
Clin Cancer Res
|
2005
|
2.76
|
|
9
|
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
|
Cancer Discov
|
2012
|
2.68
|
|
10
|
Microarrays: retracing steps.
|
Nat Med
|
2007
|
2.39
|
|
11
|
microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival.
|
Blood
|
2010
|
2.25
|
|
12
|
The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales.
|
Brief Funct Genomic Proteomic
|
2005
|
2.08
|
|
13
|
Applications of beta-mixture models in bioinformatics.
|
Bioinformatics
|
2005
|
2.04
|
|
14
|
Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression.
|
J Biol Chem
|
2006
|
2.01
|
|
15
|
Bayesian analysis of mass spectrometry proteomic data using wavelet-based functional mixed models.
|
Biometrics
|
2007
|
2.01
|
|
16
|
A comprehensive approach to the analysis of matrix-assisted laser desorption/ionization-time of flight proteomics spectra from serum samples.
|
Proteomics
|
2003
|
2.01
|
|
17
|
The bimodality index: a criterion for discovering and ranking bimodal signatures from cancer gene expression profiling data.
|
Cancer Inform
|
2009
|
1.98
|
|
18
|
Run batch effects potentially compromise the usefulness of genomic signatures for ovarian cancer.
|
J Clin Oncol
|
2008
|
1.96
|
|
19
|
Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells.
|
Mol Cancer Ther
|
2008
|
1.92
|
|
20
|
Obtaining reliable information from minute amounts of RNA using cDNA microarrays.
|
BMC Genomics
|
2002
|
1.75
|
|
21
|
Variable slope normalization of reverse phase protein arrays.
|
Bioinformatics
|
2009
|
1.66
|
|
22
|
Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients.
|
Clin Cancer Res
|
2011
|
1.59
|
|
23
|
Enrichment analysis in high-throughput genomics - accounting for dependency in the NULL.
|
Brief Bioinform
|
2006
|
1.52
|
|
24
|
Prognostic impact and targeting of CRM1 in acute myeloid leukemia.
|
Blood
|
2013
|
1.52
|
|
25
|
Analysis of mass spectrometry profiles of the serum proteome.
|
Clin Chem
|
2005
|
1.46
|
|
26
|
Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.
|
Blood
|
2008
|
1.46
|
|
27
|
Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery.
|
J Proteome Res
|
2005
|
1.45
|
|
28
|
Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia.
|
Blood
|
2010
|
1.43
|
|
29
|
Validation of oligonucleotide microarray data using microfluidic low-density arrays: a new statistical method to normalize real-time RT-PCR data.
|
Biotechniques
|
2005
|
1.39
|
|
30
|
miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue.
|
Head Neck
|
2009
|
1.38
|
|
31
|
Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy.
|
Clin Cancer Res
|
2010
|
1.38
|
|
32
|
Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia.
|
Blood
|
2011
|
1.34
|
|
33
|
Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome.
|
PLoS One
|
2010
|
1.33
|
|
34
|
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer.
|
Clin Proteomics
|
2011
|
1.32
|
|
35
|
Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia.
|
Clin Cancer Res
|
2010
|
1.30
|
|
36
|
Gene expression profile of metastatic human pancreatic cancer cells depends on the organ microenvironment.
|
Cancer Res
|
2007
|
1.29
|
|
37
|
Bayesian shrinkage estimation of the relative abundance of mRNA transcripts using SAGE.
|
Biometrics
|
2003
|
1.28
|
|
38
|
High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia.
|
Blood
|
2003
|
1.28
|
|
39
|
Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines.
|
Breast Cancer Res Treat
|
2009
|
1.25
|
|
40
|
Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress.
|
J Clin Invest
|
2010
|
1.25
|
|
41
|
Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML.
|
Blood
|
2012
|
1.25
|
|
42
|
Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus.
|
PLoS One
|
2012
|
1.24
|
|
43
|
Stem cell-ness: a "magic marker" for cancer.
|
J Clin Invest
|
2005
|
1.20
|
|
44
|
Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry.
|
Breast Cancer Res Treat
|
2005
|
1.20
|
|
45
|
What information should be required to support clinical "omics" publications?
|
Clin Chem
|
2011
|
1.19
|
|
46
|
Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.
|
Eur J Cancer
|
2011
|
1.16
|
|
47
|
Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML.
|
Blood
|
2010
|
1.15
|
|
48
|
PrepMS: TOF MS data graphical preprocessing tool.
|
Bioinformatics
|
2006
|
1.13
|
|
49
|
Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene.
|
Leuk Res
|
2008
|
1.11
|
|
50
|
Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence.
|
J Thorac Oncol
|
2010
|
1.08
|
|
51
|
Transcriptomic architecture of the adjacent airway field cancerization in non-small cell lung cancer.
|
J Natl Cancer Inst
|
2014
|
1.04
|
|
52
|
Zonal heterogeneity for gene expression in human pancreatic carcinoma.
|
Cancer Res
|
2007
|
1.03
|
|
53
|
Relax with CouchDB--into the non-relational DBMS era of bioinformatics.
|
Genomics
|
2012
|
1.02
|
|
54
|
Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells.
|
PLoS One
|
2013
|
1.01
|
|
55
|
SIBER: systematic identification of bimodally expressed genes using RNAseq data.
|
Bioinformatics
|
2013
|
1.00
|
|
56
|
Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia.
|
Cancer Res
|
2010
|
0.99
|
|
57
|
Merging microarray data, robust feature selection, and predicting prognosis in prostate cancer.
|
Cancer Inform
|
2007
|
0.99
|
|
58
|
Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.
|
J Natl Cancer Inst
|
2014
|
0.99
|
|
59
|
Use of reverse phase protein microarrays to study protein expression in leukemia: technical and methodological lessons learned.
|
Methods Mol Biol
|
2011
|
0.96
|
|
60
|
Analysis of dose-response effects on gene expression data with comparison of two microarray platforms.
|
Bioinformatics
|
2005
|
0.95
|
|
61
|
Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells.
|
Ann Hematol
|
2012
|
0.94
|
|
62
|
Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer.
|
Int J Oncol
|
2005
|
0.94
|
|
63
|
Independent validation of a model using cell line chemosensitivity to predict response to therapy.
|
J Natl Cancer Inst
|
2013
|
0.92
|
|
64
|
Ovarian cancer: linking genomics to new target discovery and molecular markers--the way ahead.
|
Adv Exp Med Biol
|
2008
|
0.92
|
|
65
|
Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology.
|
J Mol Diagn
|
2007
|
0.92
|
|
66
|
Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling.
|
Cancer Prev Res (Phila)
|
2012
|
0.92
|
|
67
|
Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression.
|
Mod Pathol
|
2010
|
0.90
|
|
68
|
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
|
Gynecol Oncol
|
2012
|
0.89
|
|
69
|
Bias, randomization, and ovarian proteomic data: a reply to "producers and consumers".
|
Cancer Inform
|
2005
|
0.89
|
|
70
|
Inter-gene correlation on oligonucleotide arrays: how much does normalization matter?
|
Am J Pharmacogenomics
|
2005
|
0.88
|
|
71
|
Reproducibility of SELDI Spectra Across Time and Laboratories.
|
Cancer Inform
|
2011
|
0.87
|
|
72
|
Response to Preprocessing of oligonucleotide array data.
|
Nat Biotechnol
|
2004
|
0.86
|
|
73
|
Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition.
|
BMC Genomics
|
2014
|
0.85
|
|
74
|
Sources of variation in false discovery rate estimation include sample size, correlation, and inherent differences between groups.
|
BMC Bioinformatics
|
2012
|
0.85
|
|
75
|
Gene sequence signatures revealed by mining the UniGene affiliation network.
|
Bioinformatics
|
2005
|
0.85
|
|
76
|
Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.
|
Gynecol Oncol
|
2011
|
0.85
|
|
77
|
Individualized molecular medicine: linking functional proteomics to select therapeutics targeting the PI3K pathway for specific patients.
|
Adv Exp Med Biol
|
2008
|
0.85
|
|
78
|
LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients.
|
Blood
|
2011
|
0.83
|
|
79
|
A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells.
|
Oncogene
|
2004
|
0.83
|
|
80
|
Biological validation of differentially expressed genes in chronic lymphocytic leukemia identified by applying multiple statistical methods to oligonucleotide microarrays.
|
J Mol Diagn
|
2005
|
0.82
|
|
81
|
Tissue-specific function of lymph node fibroblastic reticulum cells.
|
Pathobiology
|
2006
|
0.82
|
|
82
|
targetHub: a programmable interface for miRNA-gene interactions.
|
Bioinformatics
|
2013
|
0.81
|
|
83
|
integIRTy: a method to identify genes altered in cancer by accounting for multiple mechanisms of regulation using item response theory.
|
Bioinformatics
|
2012
|
0.80
|
|
84
|
Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypes.
|
J Mol Diagn
|
2012
|
0.80
|
|
85
|
Establishment and characterization by gene expression profiling of a new diffuse large B-cell lymphoma cell line, EJ-1, carrying t(14;18) and t(8;14) translocations.
|
Lab Invest
|
2003
|
0.79
|
|
86
|
A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia.
|
PLoS One
|
2011
|
0.79
|
|
87
|
Latent Feature Decompositions for Integrative Analysis of Multi-Platform Genomic Data.
|
IEEE/ACM Trans Comput Biol Bioinform
|
2014
|
0.78
|
|
88
|
Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer.
|
Surgery
|
2004
|
0.77
|
|
89
|
Statistical contributions to proteomic research.
|
Methods Mol Biol
|
2010
|
0.77
|
|
90
|
Host lung gene expression patterns predict infectious etiology in a mouse model of pneumonia.
|
Respir Res
|
2010
|
0.77
|
|
91
|
Blasted cell line names.
|
Cancer Inform
|
2010
|
0.75
|